{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:42:04Z","timestamp":1784774524605,"version":"3.55.0"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803642"],"award-info":[{"award-number":["81803642"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Specially Appointed Medical Expert Project of Jiangsu Commission of Health","award":["2019"],"award-info":[{"award-number":["2019"]}]},{"DOI":"10.13039\/501100013151","name":"Scientific Research Foundation for Returned Scholars of Ministry of Education","doi-asserted-by":"publisher","award":["2020"],"award-info":[{"award-number":["2020"]}],"id":[{"id":"10.13039\/501100013151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00204-022-03418-8","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:59:35Z","timestamp":1669298375000},"page":"377-392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Proactive therapeutic drug monitoring of vincristine in pediatric and adult cancer patients: current supporting evidence and future efforts"],"prefix":"10.1007","volume":"97","author":[{"given":"Chun-Ying","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Chao","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Rong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Ren","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8895-2350","authenticated-orcid":false,"given":"Ya-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"key":"3418_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.114143","volume":"203","author":"L Agu","year":"2021","unstructured":"Agu L, Skiles JL, Masters AR, Renbarger JL, Chow DS (2021) Simultaneous quantification of vincristine and its major M1 metabolite from dried blood spot samples of Kenyan pediatric cancer patients by UPLC-MS\/MS. J Pharm Biomed Anal 203:114143. https:\/\/doi.org\/10.1016\/j.jpba.2021.114143","journal-title":"J Pharm Biomed Anal"},{"key":"3418_CR2","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/pbc.23039","volume":"57","author":"DL Anghelescu","year":"2011","unstructured":"Anghelescu DL, Faughnan LG, Jeha S, Relling MV, Hinds PS, Sandlund JT, Cheng C, Pei D, Hankins G, Pauley JL et al (2011) Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 57:1147\u20131153. https:\/\/doi.org\/10.1002\/pbc.23039","journal-title":"Pediatr Blood Cancer"},{"key":"3418_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejca.2021.09.014","volume":"164","author":"S Barnett","year":"2022","unstructured":"Barnett S, Hellmann F, Parke E, Makin G, Tweddle DA, Osborne C, Hempel G, Veal GJ (2022) Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients. Eur J Cancer 164:127\u2013136. https:\/\/doi.org\/10.1016\/j.ejca.2021.09.014","journal-title":"Eur J Cancer"},{"key":"3418_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/0091270006288953","volume":"46","author":"AY Bedikian","year":"2006","unstructured":"Bedikian AY, Vardeleon A, Smith T, Campbell S, Namdari R (2006) Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. J Clin Pharmacol 46:727\u2013737. https:\/\/doi.org\/10.1177\/0091270006288953","journal-title":"J Clin Pharmacol"},{"key":"3418_CR5","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1177\/0091270010381499","volume":"51","author":"AY Bedikian","year":"2011","unstructured":"Bedikian AY, Silverman JA, Papadopoulos NE, Kim KB, Hagey AE, Vardeleon A, Hwu WJ, Homsi J, Davies M, Hwu P (2011) Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. J Clin Pharmacol 51:1205\u20131212. https:\/\/doi.org\/10.1177\/0091270010381499","journal-title":"J Clin Pharmacol"},{"key":"3418_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.phrs.2010.01.007","volume":"61","author":"JW Behan","year":"2010","unstructured":"Behan JW, Avramis VI, Yun JP, Louie SG, Mittelman SD (2010) Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice. Pharmacol Res 61:385\u2013390. https:\/\/doi.org\/10.1016\/j.phrs.2010.01.007","journal-title":"Pharmacol Res"},{"key":"3418_CR7","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/cpt1977224430","volume":"22","author":"RA Bender","year":"1977","unstructured":"Bender RA, Castle MC, Margileth DA, Oliverio VT (1977) The pharmacokinetics of [3H]-vincristine in man. Clin Pharmacol Ther 22:430\u2013435. https:\/\/doi.org\/10.1002\/cpt1977224430","journal-title":"Clin Pharmacol Ther"},{"key":"3418_CR8","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/cpt.1124","volume":"105","author":"JH Beumer","year":"2019","unstructured":"Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, Kim TW, Mathijssen RH, Zhang L, Arnold D et al (2019) Therapeutic drug monitoring in oncology: international association of therapeutic drug monitoring and clinical toxicology recommendations for 5-fluorouracil therapy. Clin Pharmacol Ther 105:598\u2013613. https:\/\/doi.org\/10.1002\/cpt.1124","journal-title":"Clin Pharmacol Ther"},{"key":"3418_CR9","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.clinthera.2015.10.017","volume":"38","author":"M Bosilkovska","year":"2016","unstructured":"Bosilkovska M, Ing Lorenzini K, Uppugunduri CR, Desmeules J, Daali Y, Escher M (2016) Severe vincristine-induced neuropathic pain in a CYP3A5 nonexpressor with reduced CYP3A4\/5 activity: case study. Clin Ther 38:216\u2013220. https:\/\/doi.org\/10.1016\/j.clinthera.2015.10.017","journal-title":"Clin Ther"},{"key":"3418_CR10","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/s1470-2045(10)70206-0","volume":"11","author":"A Broyl","year":"2010","unstructured":"Broyl A, Corthals SL, Jongen JLM, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM et al (2010) Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65\/GMMG-HD4 trial. Lancet Oncol 11:1057\u20131065. https:\/\/doi.org\/10.1016\/s1470-2045(10)70206-0","journal-title":"Lancet Oncol"},{"key":"3418_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.neulet.2014.10.014","volume":"596","author":"VA Carozzi","year":"2015","unstructured":"Carozzi VA, Canta A, Chiorazzi A (2015) Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms? Neurosci Lett 596:90\u2013107. https:\/\/doi.org\/10.1016\/j.neulet.2014.10.014","journal-title":"Neurosci Lett"},{"key":"3418_CR12","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/annonc\/mdh348","volume":"15","author":"G Cavaletti","year":"2004","unstructured":"Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, Franchi D, La Presa MT, Lissoni A, Buda A et al (2004) Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol 15:1439\u20131442. https:\/\/doi.org\/10.1093\/annonc\/mdh348","journal-title":"Ann Oncol"},{"key":"3418_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1529-8027.2007.00141.x","volume":"12","author":"G Cavaletti","year":"2007","unstructured":"Cavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C, Zara G, Plasmati R, Pastorelli F, Caraceni A et al (2007) The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the national cancer institute-common toxicity scale. J Peripher Nerv Syst 12:210\u2013215. https:\/\/doi.org\/10.1111\/j.1529-8027.2007.00141.x","journal-title":"J Peripher Nerv Syst"},{"key":"3418_CR14","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.2217\/pgs.14.68","volume":"15","author":"F Ceppi","year":"2014","unstructured":"Ceppi F, Langlois-Pelletier C, Gagne V, Rousseau J, Ciolino C, De Lorenzo S, Kevin KM, Cijov D, Sallan SE, Silverman LB et al (2014) Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics 15:1105\u20131116. https:\/\/doi.org\/10.2217\/pgs.14.68","journal-title":"Pharmacogenomics"},{"key":"3418_CR15","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1007\/s00520-019-04987-8","volume":"27","author":"A Chan","year":"2019","unstructured":"Chan A, Hertz DL, Morales M, Adams EJ, Gordon S, Tan CJ, Staff NP, Kamath J, Oh J, Shinde S et al (2019) Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. Support Care Cancer 27:3729\u20133737. https:\/\/doi.org\/10.1007\/s00520-019-04987-8","journal-title":"Support Care Cancer"},{"key":"3418_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ejca.2021.08.033","volume":"157","author":"WA Clarke","year":"2021","unstructured":"Clarke WA, Chatelut E, Fotoohi AK, Larson RA, Martin JH, Mathijssen RHJ, Salamone SJ (2021) Therapeutic drug monitoring in oncology: international association of therapeutic drug monitoring and clinical toxicology consensus guidelines for imatinib therapy. Eur J Cancer 157:428\u2013440. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.033","journal-title":"Eur J Cancer"},{"key":"3418_CR17","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/s0022-3476(94)70027-3","volume":"125","author":"WR Crom","year":"1994","unstructured":"Crom WR, de Graaf SS, Synold T, Uges DR, Bloemhof H, Rivera G, Christensen ML, Mahmoud H, Evans WE (1994) Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr 125:642\u2013649. https:\/\/doi.org\/10.1016\/s0022-3476(94)70027-3","journal-title":"J Pediatr"},{"key":"3418_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jchromb.2008.04.046","volume":"868","author":"CW Damen","year":"2008","unstructured":"Damen CW, Rosing H, Tibben MM, van Maanen MJ, Lagas JS, Schinkel AH, Schellens JH, Beijnen JH (2008) A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 868:102\u2013109. https:\/\/doi.org\/10.1016\/j.jchromb.2008.04.046","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"3418_CR19","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00216-009-2775-z","volume":"394","author":"CW Damen","year":"2009","unstructured":"Damen CW, Rosing H, Schellens JH, Beijnen JH (2009) Application of dried blood spots combined with high-performance liquid chromatography coupled with electrospray ionisation tandem mass spectrometry for simultaneous quantification of vincristine and actinomycin-D. Anal Bioanal Chem 394:1171\u20131182. https:\/\/doi.org\/10.1007\/s00216-009-2775-z","journal-title":"Anal Bioanal Chem"},{"key":"3418_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/mpo.2950240405","volume":"24","author":"SS de Graaf","year":"1995","unstructured":"de Graaf SS, Bloemhof H, Vendrig DE, Uges DR (1995) Vincristine disposition in children with acute lymphoblastic leukemia. Med Pediatr Oncol 24:235\u2013240. https:\/\/doi.org\/10.1002\/mpo.2950240405","journal-title":"Med Pediatr Oncol"},{"key":"3418_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.clml.2013.10.012","volume":"14","author":"OR Deitcher","year":"2014","unstructured":"Deitcher OR, Glaspy J, Gonzalez R, Sato T, Bedikian AY, Segarini K, Silverman J, Deitcher SR (2014) High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity. Clin Lymphoma Myeloma Leuk 14:197\u2013202. https:\/\/doi.org\/10.1016\/j.clml.2013.10.012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3418_CR22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1124\/dmd.106.009902","volume":"34","author":"JB Dennison","year":"2006","unstructured":"Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD (2006) Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 34:1317\u20131327. https:\/\/doi.org\/10.1124\/dmd.106.009902","journal-title":"Drug Metab Dispos"},{"key":"3418_CR23","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1124\/jpet.106.118471","volume":"321","author":"JB Dennison","year":"2007","unstructured":"Dennison JB, Jones DR, Renbarger JL, Hall SD (2007) Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 321:553\u2013563. https:\/\/doi.org\/10.1124\/jpet.106.118471","journal-title":"J Pharmacol Exp Ther"},{"key":"3418_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/FTD.0b013e31816b92c9","volume":"30","author":"JB Dennison","year":"2008","unstructured":"Dennison JB, Renbarger JL, Walterhouse DO, Jones DR, Hall SD (2008) Quantification of vincristine and its major metabolite in human plasma by high-performance liquid chromatography\/tandem mass spectrometry. Ther Drug Monit 30:357\u2013364. https:\/\/doi.org\/10.1097\/FTD.0b013e31816b92c9","journal-title":"Ther Drug Monit"},{"key":"3418_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/BF00255486","volume":"8","author":"ZR Desai","year":"1982","unstructured":"Desai ZR, Berg, H.W.V.d., Bridges, J.M., and Shanks, R.G. (1982) Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 8:211\u2013214. https:\/\/doi.org\/10.1007\/BF00255486","journal-title":"Cancer Chemother Pharmacol"},{"key":"3418_CR26","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jama.2015.0894","volume":"313","author":"B Diouf","year":"2015","unstructured":"Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, Zheng JJ, Yang W, Fan Y, Wheeler HE et al (2015) Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313:815\u2013823. https:\/\/doi.org\/10.1001\/jama.2015.0894","journal-title":"JAMA"},{"key":"3418_CR27","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1634\/theoncologist.2015-0391","volume":"21","author":"D Douer","year":"2016","unstructured":"Douer D (2016) Efficacy and safety of vincristine sulfate liposome injection in the treatment of adult acute lymphocytic leukemia. Oncologist 21:840\u2013847. https:\/\/doi.org\/10.1634\/theoncologist.2015-0391","journal-title":"Oncologist"},{"key":"3418_CR28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/pbc.22845","volume":"56","author":"A Egbelakin","year":"2011","unstructured":"Egbelakin A, Ferguson MJ, MacGill EA, Lehmann AS, Topletz AR, Quinney SK, Li L, McCammack KC, Hall SD, Renbarger JL (2011) Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 56:361\u2013367. https:\/\/doi.org\/10.1002\/pbc.22845","journal-title":"Pediatr Blood Cancer"},{"key":"3418_CR29","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/s0731-7085(97)00087-3","volume":"16","author":"L Embree","year":"1997","unstructured":"Embree L, Gelmon KA, Tolcher AW, Hudon NJ, Heggie JR, Dedhar C, Webb MS, Bally MB, Mayer LD (1997) Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. J Pharm Biomed Anal 16:675\u2013687. https:\/\/doi.org\/10.1016\/s0731-7085(97)00087-3","journal-title":"J Pharm Biomed Anal"},{"key":"3418_CR30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s002800050750","volume":"41","author":"L Embree","year":"1998","unstructured":"Embree L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, Logan P, Bally MB, Mayer LD (1998) Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol 41:347\u2013352. https:\/\/doi.org\/10.1007\/s002800050750","journal-title":"Cancer Chemother Pharmacol"},{"key":"3418_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1529-8027.2011.00351.x","volume":"16","author":"B Frigeni","year":"2011","unstructured":"Frigeni B, Piatti M, Lanzani F, Alberti P, Villa P, Zanna C, Ceracchi M, Ildebrando M, Cavaletti G (2011) Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the national cancer institute common toxicity scale. J Peripher Nerv Syst 16:228\u2013236. https:\/\/doi.org\/10.1111\/j.1529-8027.2011.00351.x","journal-title":"J Peripher Nerv Syst"},{"key":"3418_CR32","doi-asserted-by":"crossref","unstructured":"Frost BM, L\u00f6nnerholm G, Koopmans P, Abrahamsson J, Behrendtz M, Castor A, Forestier E, Uges DR, de Graaf SS (2003) Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta paediatrica (Oslo, Norway : 1992) 92, 551\u2013557.","DOI":"10.1111\/j.1651-2227.2003.tb02505.x"},{"key":"3418_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s002800050968","volume":"44","author":"CE Gidding","year":"1999","unstructured":"Gidding CE, Meeuwsen-de Boer GJ, Koopmans P, Uges DR, Kamps WA, de Graaf SS (1999) Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol 44:203\u2013209. https:\/\/doi.org\/10.1007\/s002800050968","journal-title":"Cancer Chemother Pharmacol"},{"key":"3418_CR34","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00520-012-1591-8","volume":"21","author":"LS Gilchrist","year":"2013","unstructured":"Gilchrist LS, Tanner L (2013) The pediatric-modified total neuropathy score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers. Support Care Cancer 21:847\u2013856. https:\/\/doi.org\/10.1007\/s00520-012-1591-8","journal-title":"Support Care Cancer"},{"key":"3418_CR35","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00520-013-1981-6","volume":"22","author":"LS Gilchrist","year":"2014","unstructured":"Gilchrist LS, Marais L, Tanner L (2014) Comparison of two chemotherapy-induced peripheral neuropathy measurement approaches in children. Support Care Cancer 22:359\u2013366. https:\/\/doi.org\/10.1007\/s00520-013-1981-6","journal-title":"Support Care Cancer"},{"key":"3418_CR36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12098-009-0254-3","volume":"77","author":"S Gomber","year":"2010","unstructured":"Gomber S, Dewan P, Chhonker D (2010) Vincristine induced neurotoxicity in cancer patients. Indian J Pediatr 77:97\u2013100. https:\/\/doi.org\/10.1007\/s12098-009-0254-3","journal-title":"Indian J Pediatr"},{"key":"3418_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1203\/00006450-200207000-00021","volume":"52","author":"E Groninger","year":"2002","unstructured":"Groninger E, Meeuwsen-de Boar T, Koopmans P, Uges D, Sluiter W, Veerman A, Kamps W, de Graaf S (2002) Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. Pediatr Res 52:113\u2013118. https:\/\/doi.org\/10.1203\/00006450-200207000-00021","journal-title":"Pediatr Res"},{"key":"3418_CR38","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejca.2004.10.006","volume":"41","author":"E Groninger","year":"2005","unstructured":"Groninger E, Meeuwsen-de Boer T, Koopmans P, Uges D, Sluiter W, Veerman A, Kamps W, de Graaf S (2005) Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG). Eur J Cancer 41:98\u2013103. https:\/\/doi.org\/10.1016\/j.ejca.2004.10.006","journal-title":"Eur J Cancer"},{"key":"3418_CR39","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00280-010-1541-4","volume":"68","author":"R Guilhaumou","year":"2011","unstructured":"Guilhaumou R, Simon N, Quaranta S, Verschuur A, Lacarelle B, Andre N, Solas C (2011) Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases. Cancer Chemother Pharmacol 68:1191\u20131198. https:\/\/doi.org\/10.1007\/s00280-010-1541-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"3418_CR40","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41397-017-0003-3","volume":"18","author":"A Gutierrez-Camino","year":"2018","unstructured":"Gutierrez-Camino A, Umerez M, Martin-Guerrero I, Garcia de Andoin N, Santos B, Sastre A, Echebarria-Barona A, Astigarraga I, Navajas A, Garcia-Orad A (2018) Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia. Pharmacogenomics J 18:704\u2013712. https:\/\/doi.org\/10.1038\/s41397-017-0003-3","journal-title":"Pharmacogenomics J"},{"key":"3418_CR41","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1002\/1097-0142(19940515)73:10<2515::aid-cncr2820731011>3.0.co;2-g","volume":"73","author":"N Haim","year":"1994","unstructured":"Haim N, Epelbaum R, Ben-Shahar M, Yarnitsky D, Simri W, Robinson E (1994) Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 73:2515\u20132519. https:\/\/doi.org\/10.1002\/1097-0142(19940515)73:10%3c2515::aid-cncr2820731011%3e3.0.co;2-g","journal-title":"Cancer"},{"key":"3418_CR42","doi-asserted-by":"publisher","first-page":"E111","DOI":"10.1188\/17.ONF.E111-E123","volume":"44","author":"H Haryani","year":"2017","unstructured":"Haryani H, Fetzer SJ, Wu CL, Hsu YY (2017) Chemotherapy-Induced Peripheral Neuropathy Assessment Tools: A Systematic Review. Oncol Nurs Forum 44:E111\u2013E123. https:\/\/doi.org\/10.1188\/17.ONF.E111-E123","journal-title":"Oncol Nurs Forum"},{"key":"3418_CR43","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ijporl.2018.08.017","volume":"114","author":"A Hseu","year":"2018","unstructured":"Hseu A, Ayele N, Kawai K, Frazier AL, Mack J, Watters K, Nuss R, Rahbar R (2018) Pediatric vincristine-related vocal fold paralysis. Int J Pediatr Otorhinolaryngol 114:166\u2013169. https:\/\/doi.org\/10.1016\/j.ijporl.2018.08.017","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"3418_CR44","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/j.bcp.2006.03.009","volume":"71","author":"R Huang","year":"2006","unstructured":"Huang R, Murry DJ, Kolwankar D, Hall SD, Foster DR (2006) Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem Pharmacol 71:1695\u20131704. https:\/\/doi.org\/10.1016\/j.bcp.2006.03.009","journal-title":"Biochem Pharmacol"},{"key":"3418_CR45","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","volume":"30","author":"SP Hunger","year":"2012","unstructured":"Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, Reaman GH, Carroll WL (2012) Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group. J Clin Oncol 30:1663\u20131669. https:\/\/doi.org\/10.1200\/JCO.2011.37.8018","journal-title":"J Clin Oncol"},{"key":"3418_CR46","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00280-020-04220-y","volume":"87","author":"T Igarashi","year":"2021","unstructured":"Igarashi T, Kishi S, Hosono N, Higashi T, Iwao T, Yano R, Tsukamoto H, Goto N, Yamauchi T, Ueda T (2021) Population pharmacokinetic model development and exposure-response analysis of vincristine in patients with malignant lymphoma. Cancer Chemother Pharmacol 87:501\u2013511. https:\/\/doi.org\/10.1007\/s00280-020-04220-y","journal-title":"Cancer Chemother Pharmacol"},{"key":"3418_CR47","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/cpt1978241101","volume":"24","author":"DV Jackson Jr","year":"1978","unstructured":"Jackson DV Jr, Castle MC, Bender RA (1978) Biliary excretion of vincristine. Clin Pharmacol Ther 24:101\u2013107. https:\/\/doi.org\/10.1002\/cpt1978241101","journal-title":"Clin Pharmacol Ther"},{"key":"3418_CR48","first-page":"1043","volume":"65","author":"DV Jackson Jr","year":"1981","unstructured":"Jackson DV Jr, Sethi VS, Spurr CL, White DR, Richards F 2nd, Stuart JJ, Muss HB, Cooper MR, Castle MC (1981a) Pharmacokinetics of vincristine infusion. Cancer Treat Rep 65:1043\u20131048","journal-title":"Cancer Treat Rep"},{"key":"3418_CR49","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1002\/1097-0142(19811215)48:12<2559::aid-cncr2820481203>3.0.co;2-6","volume":"48","author":"DV Jackson Jr","year":"1981","unstructured":"Jackson DV Jr, Sethi VS, Spurr CL, Willard V, White DR, Richards F 2nd, Stuart JJ, Muss HB, Cooper MR, Homesley HD et al (1981b) Intravenous vincristine infusion: phase I trial. Cancer 48:2559\u20132564. https:\/\/doi.org\/10.1002\/1097-0142(19811215)48:12%3c2559::aid-cncr2820481203%3e3.0.co;2-6","journal-title":"Cancer"},{"key":"3418_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2021.122591","volume":"1168","author":"Y Jin","year":"2021","unstructured":"Jin Y, Li Y, Uddin ME, Sparreboom A, Hu S (2021) Rapid quantification of vincristine in mouse plasma using ESI-LC-MS\/MS: application to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 1168:122591. https:\/\/doi.org\/10.1016\/j.jchromb.2021.122591","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"3418_CR51","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/mph.0000000000000910","volume":"39","author":"H Kayilio\u011flu","year":"2017","unstructured":"Kayilio\u011flu H, Kocak U, Kan Karaer D, Percin EF, Sal E, Tekkesin F, Isik M, Oner N, Belen FB, Yilmaz Keskin E et al (2017) Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population. J Pediatr Hematol Oncol 39:458\u2013462. https:\/\/doi.org\/10.1097\/mph.0000000000000910","journal-title":"J Pediatr Hematol Oncol"},{"key":"3418_CR52","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/cncr.10397","volume":"94","author":"SJ Kellie","year":"2002","unstructured":"Kellie SJ, Barbaric D, Koopmans P, Earl J, Carr DJ, de Graaf SS (2002) Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration. Cancer 94:1815\u20131820. https:\/\/doi.org\/10.1002\/cncr.10397","journal-title":"Cancer"},{"key":"3418_CR53","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1002\/cncr.20220","volume":"100","author":"SJ Kellie","year":"2004","unstructured":"Kellie SJ, Koopmans P, Earl J, Nath C, Roebuck D, Uges DR, De Graaf SS (2004) Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors. Cancer 100:2637\u20132643. https:\/\/doi.org\/10.1002\/cncr.20220","journal-title":"Cancer"},{"key":"3418_CR54","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12944-016-0318-0","volume":"15","author":"HA Khalil","year":"2016","unstructured":"Khalil HA, Belal TS, El-Yazbi AF, Hamdy DA (2016) The effect of increased lipoproteins levels on the disposition of vincristine in rat. Lipids Health Dis 15:152. https:\/\/doi.org\/10.1186\/s12944-016-0318-0","journal-title":"Lipids Health Dis"},{"key":"3418_CR55","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40268-017-0178-8","volume":"17","author":"HA Khalil","year":"2017","unstructured":"Khalil HA, ElKhatib MAW, Belal TS, El-Yazbi AF, Hamdy DA (2017) Hyperlipidemia alters the pharmacokinetics of posaconazole and vincristine upon co-administration in rats. Drugs R D 17:287\u2013296. https:\/\/doi.org\/10.1007\/s40268-017-0178-8","journal-title":"Drugs R D"},{"key":"3418_CR56","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jchromb.2017.10.054","volume":"1072","author":"M Kiani","year":"2018","unstructured":"Kiani M, Qomi M, Hashemian F, Rajabi M (2018) Multivariate optimization of solvent bar microextraction combined with HPLC-UV for determination of trace amounts of vincristine in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 1072:397\u2013404. https:\/\/doi.org\/10.1016\/j.jchromb.2017.10.054","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"3418_CR57","doi-asserted-by":"crossref","unstructured":"Kidd JM, Asempa TE, Abdelraouf K (2021) Chapter 13\u2014Therapeutic drug monitoring. In Remington (Twenty-third Edition), A. Adejare, ed. (Academic Press), pp. 243\u2013262.","DOI":"10.1016\/B978-0-12-820007-0.00013-1"},{"key":"3418_CR58","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/00007691-200108000-00014","volume":"23","author":"P Koopmans","year":"2001","unstructured":"Koopmans P, Gidding CE, de Graaf SS, Uges DR (2001) An automated method for the bioanalysis of vincristine suitable for therapeutic drug monitoring and pharmacokinetic studies in young children. Ther Drug Monit 23:406\u2013409. https:\/\/doi.org\/10.1097\/00007691-200108000-00014","journal-title":"Ther Drug Monit"},{"key":"3418_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2022.107337","author":"P Kozlik","year":"2022","unstructured":"Kozlik P, Sirc J, Cocarta A-I, Bosakova Z (2022) A novel highly sensitive UHPLC-MS\/MS method for monitoring vincristine in plasma and vitreous humor samples with potential application in retinoblastoma therapy. Microchem J. https:\/\/doi.org\/10.1016\/j.microc.2022.107337","journal-title":"Microchem J"},{"key":"3418_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222155","author":"C Krieckaert","year":"2022","unstructured":"Krieckaert C, van Tubergen A, Gehin J, Hern\u00e1ndez-Breijo B, Le M\u00e9l\u00e9do G, Balsa A, B\u00f6hm P, Cucnik S, Elkayam O, Goll G et al (2022) EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222155","journal-title":"Ann Rheum Dis"},{"key":"3418_CR61","doi-asserted-by":"publisher","first-page":"E49","DOI":"10.1097\/NCC.0b013e318299ad23","volume":"36","author":"EM Lavoie Smith","year":"2013","unstructured":"Lavoie Smith EM, Li L, Hutchinson RJ, Ho R, Burnette WB, Wells E, Bridges C, Renbarger J (2013) Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer Nurs 36:E49-60. https:\/\/doi.org\/10.1097\/NCC.0b013e318299ad23","journal-title":"Cancer Nurs"},{"key":"3418_CR62","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/psp4.12453","volume":"8","author":"CM Lee","year":"2019","unstructured":"Lee CM, Zane NR, Veal G, Thakker DR (2019) Physiologically Based Pharmacokinetic Models for Adults and Children Reveal a Role of Intracellular Tubulin Binding in Vincristine Disposition. CPT Pharmacometrics Syst Pharmacol 8:759\u2013768. https:\/\/doi.org\/10.1002\/psp4.12453","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"3418_CR63","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3324\/haematol.2019.237230","volume":"106","author":"G Lew","year":"2021","unstructured":"Lew G, Chen Y, Lu X, Rheingold SR, Whitlock JA, Devidas M, Hastings CA, Winick NJ, Carroll WL, Wood BL et al (2021) Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group phase III study AALL0433. Haematologica 106:46\u201355. https:\/\/doi.org\/10.3324\/haematol.2019.237230","journal-title":"Haematologica"},{"key":"3418_CR64","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.neuro.2020.10.004","volume":"81","author":"GZ Li","year":"2020","unstructured":"Li GZ, Hu YH, Li DY, Zhang Y, Guo HL, Li YM, Chen F, Xu J (2020a) Vincristine-induced peripheral neuropathy: A mini-review. Neurotoxicology 81:161\u2013171. https:\/\/doi.org\/10.1016\/j.neuro.2020.10.004","journal-title":"Neurotoxicology"},{"key":"3418_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100653","volume":"43","author":"T Li","year":"2020","unstructured":"Li T, Timmins HC, Lazarus HM, Park SB (2020b) Peripheral neuropathy in hematologic malignancies - Past, present and future. Blood Rev 43:100653. https:\/\/doi.org\/10.1016\/j.blre.2020.100653","journal-title":"Blood Rev"},{"key":"3418_CR66","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ejpn.2017.12.019","volume":"22","author":"S Lieber","year":"2018","unstructured":"Lieber S, Blankenburg M, Apel K, Hirschfeld G, Hernaiz Driever P, Reindl T (2018) Small-fiber neuropathy and pain sensitization in survivors of pediatric acute lymphoblastic leukemia. Eur J Paediatr Neurol 22:457\u2013469. https:\/\/doi.org\/10.1016\/j.ejpn.2017.12.019","journal-title":"Eur J Paediatr Neurol"},{"key":"3418_CR67","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/j.1365-2141.2008.07235.x","volume":"142","author":"G Lonnerholm","year":"2008","unstructured":"Lonnerholm G, Frost BM, Abrahamsson J, Behrendtz M, Castor A, Forestier E, Heyman M, Uges DR, de Graaf SS (2008) Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia. Br J Haematol 142:616\u2013621. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07235.x","journal-title":"Br J Haematol"},{"key":"3418_CR68","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2217\/pgs-2016-0001","volume":"17","author":"E Lopez-Lopez","year":"2016","unstructured":"Lopez-Lopez E, Gutierrez-Camino A, Astigarraga I, Navajas A, Echebarria-Barona A, Garcia-Miguel P, Garcia de Andoin N, Lobo C, Guerra-Merino I, Martin-Guerrero I et al (2016) Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia. Pharmacogenomics 17:731\u2013741. https:\/\/doi.org\/10.2217\/pgs-2016-0001","journal-title":"Pharmacogenomics"},{"key":"3418_CR69","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00280-019-03884-5","volume":"84","author":"ML Madsen","year":"2019","unstructured":"Madsen ML, Due H, Ejskjaer N, Jensen P, Madsen J, Dybkaer K (2019) Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review. Cancer Chemother Pharmacol 84:471\u2013485. https:\/\/doi.org\/10.1007\/s00280-019-03884-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"3418_CR70","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.14678","volume":"181","author":"CA McClain","year":"2018","unstructured":"McClain CA, Bernhardt MB, Berger A, Bernini JC, Marquez-Do D, Winslow R, Scheurer ME, Schafer ES (2018) Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia. Br J Haematol 181:684\u2013687. https:\/\/doi.org\/10.1111\/bjh.14678","journal-title":"Br J Haematol"},{"key":"3418_CR71","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.coph.2020.09.006","volume":"55","author":"RP McNeill","year":"2020","unstructured":"McNeill RP, Barclay ML (2020) Cost-effectiveness of therapeutic drug monitoring in inflammatory bowel disease. Curr Opin Pharmacol 55:41\u201346. https:\/\/doi.org\/10.1016\/j.coph.2020.09.006","journal-title":"Curr Opin Pharmacol"},{"key":"3418_CR72","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/j.1440-1754.2011.02103.x","volume":"47","author":"AS Moore","year":"2011","unstructured":"Moore AS, Norris R, Price G, Nguyen T, Ni M, George R, van Breda K, Duley J, Charles B, Pinkerton R (2011) Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach. J Paediatr Child Health 47:875\u2013882. https:\/\/doi.org\/10.1111\/j.1440-1754.2011.02103.x","journal-title":"J Paediatr Child Health"},{"key":"3418_CR73","doi-asserted-by":"publisher","unstructured":"Moriyama B, Falade-Nwulia O, Leung J, Penzak SR, C, J.J., Huang X, Henning SA, Wilson WH, Walsh TJ (2011) Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction. Mycoses 54:e877-879. https:\/\/doi.org\/10.1111\/j.1439-0507.2011.02016.x","DOI":"10.1111\/j.1439-0507.2011.02016.x"},{"key":"3418_CR74","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1200\/JCO.2012.46.2309","volume":"31","author":"S O'Brien","year":"2013","unstructured":"O\u2019Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, Ben-Yehuda D, Stock W, Coutre S, Douer D et al (2013) High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol 31:676\u2013683. https:\/\/doi.org\/10.1200\/JCO.2012.46.2309","journal-title":"J Clin Oncol"},{"key":"3418_CR75","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/pbc.22972","volume":"57","author":"ZD Pana","year":"2011","unstructured":"Pana ZD, Roilides E (2011) Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: old problem - new dilemma. Pediatr Blood Cancer 57:30\u201335. https:\/\/doi.org\/10.1002\/pbc.22972","journal-title":"Pediatr Blood Cancer"},{"key":"3418_CR76","doi-asserted-by":"crossref","unstructured":"Park S, Renn CL, Lees JG, Dorsey SG, Cavaletti G, Carozzi VA (2021) Electrophysiological assessments in and in rodent models of chemotherapy-induced painful peripheral. In Experimental Neurotoxicology Methods, pp. 133\u2013161.","DOI":"10.1007\/978-1-0716-1637-6_7"},{"key":"3418_CR77","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00280-021-04302-5","volume":"88","author":"V Pilla Reddy","year":"2021","unstructured":"Pilla Reddy V, Fretland AJ, Zhou D, Sharma S, Chen B, Vishwanathan K, McGinnity DF, Xu Y, Ware JA (2021) Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors. Cancer Chemother Pharmacol 88:451\u2013464. https:\/\/doi.org\/10.1007\/s00280-021-04302-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"3418_CR78","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/17425255.2021.1855141","volume":"17","author":"E Pozzi","year":"2021","unstructured":"Pozzi E, Fumagalli G, Chiorazzi A, Canta A, Cavaletti G (2021) Genetic factors influencing the development of vincristine-induced neurotoxicity. Expert Opin Drug Metab Toxicol 17:215\u2013226. https:\/\/doi.org\/10.1080\/17425255.2021.1855141","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3418_CR79","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.2147\/ijn.S54657","volume":"8","author":"TA Raj","year":"2013","unstructured":"Raj TA, Smith AM, Moore AS (2013) Vincristine sulfate liposomal injection for acute lymphoblastic leukemia. Int J Nanomed 8:4361\u20134369. https:\/\/doi.org\/10.2147\/ijn.S54657","journal-title":"Int J Nanomed"},{"key":"3418_CR80","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/pbc.21435","volume":"50","author":"JL Renbarger","year":"2008","unstructured":"Renbarger JL, McCammack KC, Rouse CE, Hall SD (2008) Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer 50:769\u2013771. https:\/\/doi.org\/10.1002\/pbc.21435","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"3418_CR81","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1517\/17425255.2014.885016","volume":"10","author":"R Said","year":"2014","unstructured":"Said R, Tsimberidou AM (2014) Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies. Expert Opin Drug Metab Toxicol 10(3):483\u2013494","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3418_CR82","doi-asserted-by":"publisher","unstructured":"Schmiegelow K, Muller K, Mogensen SS, Mogensen PR, Wolthers BO, Stoltze UK, Tuckuviene R, Frandsen T (2017) Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. F1000Res 6:444. https:\/\/doi.org\/10.12688\/f1000research.10768.1","DOI":"10.12688\/f1000research.10768.1"},{"key":"3418_CR83","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/bf00262326","volume":"6","author":"VS Sethi","year":"1981","unstructured":"Sethi VS, Kimball JC (1981) Pharmacokinetics of vincristine sulfate in children. Cancer Chemother Pharmacol 6:111\u2013115. https:\/\/doi.org\/10.1007\/bf00262326","journal-title":"Cancer Chemother Pharmacol"},{"key":"3418_CR84","first-page":"3551","volume":"41","author":"VS Sethi","year":"1981","unstructured":"Sethi VS, Jackson DV Jr, White DR, Richards F 2nd, Stuart JJ, Muss HB, Cooper MR, Spurr CL (1981) Pharmacokinetics of vincristine sulfate in adult cancer patients. Can Res 41:3551\u20133555","journal-title":"Can Res"},{"key":"3418_CR85","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/bf00255905","volume":"12","author":"VS Sethi","year":"1984","unstructured":"Sethi VS, Surratt P, Spurr CL (1984) Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. Cancer Chemother Pharmacol 12:31\u201335. https:\/\/doi.org\/10.1007\/bf00255905","journal-title":"Cancer Chemother Pharmacol"},{"key":"3418_CR86","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10637-015-0311-x","volume":"34","author":"NN Shah","year":"2016","unstructured":"Shah NN, Cole DE, Lester-McCully CM, Wayne AS, Warren KE, Widemann BC (2016a) Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo(R)) after intravenous administration in Non-human primates. Invest New Drugs 34:61\u201365. https:\/\/doi.org\/10.1007\/s10637-015-0311-x","journal-title":"Invest New Drugs"},{"key":"3418_CR87","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/pbc.25937","volume":"63","author":"NN Shah","year":"2016","unstructured":"Shah NN, Merchant MS, Cole DE, Jayaprakash N, Bernstein D, Delbrook C, Richards K, Widemann BC, Wayne AS (2016b) Vincristine Sulfate Liposomes Injection (VSLI, Marqibo(R)): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias. Pediatr Blood Cancer 63:997\u20131005. https:\/\/doi.org\/10.1002\/pbc.25937","journal-title":"Pediatr Blood Cancer"},{"key":"3418_CR88","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00280-012-2042-4","volume":"71","author":"JA Silverman","year":"2013","unstructured":"Silverman JA, Deitcher SR (2013) Marqibo(R) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol 71:555\u2013564. https:\/\/doi.org\/10.1007\/s00280-012-2042-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"3418_CR89","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/jcph.155","volume":"53","author":"JA Silverman","year":"2013","unstructured":"Silverman JA, Reynolds L, Deitcher SR (2013) Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia. J Clin Pharmacol 53:1139\u20131145. https:\/\/doi.org\/10.1002\/jcph.155","journal-title":"J Clin Pharmacol"},{"key":"3418_CR90","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/1078155214553143","volume":"22","author":"RP Sims","year":"2016","unstructured":"Sims RP (2016) The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia. J Oncol Pharm Pract 22:76\u201381. https:\/\/doi.org\/10.1177\/1078155214553143","journal-title":"J Oncol Pharm Pract"},{"key":"3418_CR91","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26854","author":"JL Skiles","year":"2018","unstructured":"Skiles JL, Chiang C, Li CH, Martin S, Smith EL, Olbara G, Jones DR, Vik TA, Mostert S, Abbink F et al (2018) CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. Pediatr Blood Cancer. https:\/\/doi.org\/10.1002\/pbc.26854","journal-title":"Pediatr Blood Cancer"},{"key":"3418_CR92","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00280-021-04295-1","volume":"88","author":"J Skolnik","year":"2021","unstructured":"Skolnik J, Hall D, Barkauskas DA, Moorthy G, Larson TR, Fox E, Weigel BJ, Berg SL, Reid JM (2021) Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: children\u2019s oncology group study ADVL06B1. Cancer Chemother Pharmacol 88:359\u2013365. https:\/\/doi.org\/10.1007\/s00280-021-04295-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"3418_CR93","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1188\/08.ONF.96-102","volume":"35","author":"EM Smith","year":"2008","unstructured":"Smith EM, Beck SL, Cohen J (2008) The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 35:96\u2013102. https:\/\/doi.org\/10.1188\/08.ONF.96-102","journal-title":"Oncol Nurs Forum"},{"key":"3418_CR94","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/NCC.0b013e3181c989a3","volume":"33","author":"EM Smith","year":"2010","unstructured":"Smith EM, Cohen JA, Pett MA, Beck SL (2010) The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums. Cancer Nurs 33:173\u2013183. https:\/\/doi.org\/10.1097\/NCC.0b013e3181c989a3","journal-title":"Cancer Nurs"},{"key":"3418_CR95","doi-asserted-by":"publisher","unstructured":"Smith EML, Kuisell C, Cho Y, Kanzawa-Lee GA, Gilchrist LS, Park SB, Scott MR, Alberti P, Toxic Neuropathy consortium of the peripheral Nerve, S. (2021). Characteristics and patterns of pediatric chemotherapy-induced peripheral neuropathy: A systematic review. Cancer Treat Res Commun 28:100420. https:\/\/doi.org\/10.1016\/j.ctarc.2021.100420","DOI":"10.1016\/j.ctarc.2021.100420"},{"key":"3418_CR96","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/cpt.506","volume":"101","author":"W Stock","year":"2017","unstructured":"Stock W, Diouf B, Crews KR, Pei D, Cheng C, Laumann K, Mandrekar SJ, Luger S, Advani A, Stone RM et al (2017) An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia. Clin Pharmacol Ther 101:391\u2013395. https:\/\/doi.org\/10.1002\/cpt.506","journal-title":"Clin Pharmacol Ther"},{"key":"3418_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084112","author":"S Triarico","year":"2021","unstructured":"Triarico S, Romano A, Attina G, Capozza MA, Maurizi P, Mastrangelo S, Ruggiero A (2021) Vincristine-induced peripheral neuropathy (VIPN) in pediatric tumors: mechanisms, risk factors, strategies of prevention and treatment. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22084112","journal-title":"Int J Mol Sci"},{"key":"3418_CR98","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/s1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas A, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman C (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology 13:176\u2013181. https:\/\/doi.org\/10.1016\/s1053-4296(03)00031-6","journal-title":"Seminars in Radiation Oncology"},{"key":"3418_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030612","author":"A Uittenboogaard","year":"2022","unstructured":"Uittenboogaard A, Neutel CLG, Ket JCF, Njuguna F, Huitema ADR, Kaspers GJL, van de Velde ME (2022) Pharmacogenomics of vincristine-induced peripheral neuropathy in children with cancer: a systematic review and meta-analysis. Cancers (basel). https:\/\/doi.org\/10.3390\/cancers14030612","journal-title":"Cancers (basel)"},{"key":"3418_CR100","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.critrevonc.2017.04.004","volume":"114","author":"ME van de Velde","year":"2017","unstructured":"van de Velde ME, Kaspers GL, Abbink FCH, Wilhelm AJ, Ket JCF, van den Berg MH (2017) Vincristine-induced peripheral neuropathy in children with cancer: a systematic review. Crit Rev Oncol Hematol 114:114\u2013130. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.04.004","journal-title":"Crit Rev Oncol Hematol"},{"key":"3418_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071789","author":"ME van de Velde","year":"2020","unstructured":"van de Velde ME, Panetta JC, Wilhelm AJ, van den Berg MH, van der Sluis IM, van den Bos C, Abbink FCH, van den Heuvel-Eibrink MM, Segers H, Chantrain C et al (2020) Population pharmacokinetics of vincristine related to infusion duration and peripheral neuropathy in pediatric oncology patients. Cancers (basel). https:\/\/doi.org\/10.3390\/cancers12071789","journal-title":"Cancers (basel)"},{"key":"3418_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143510","author":"ME van de Velde","year":"2022","unstructured":"van de Velde ME, Uittenboogaard A, Yang W, Bonten E, Cheng C, Pei D, van den Berg MH, van der Sluis IM, van den Bos C, Abbink FCH et al (2022) Genetic polymorphisms associated with vincristine pharmacokinetics and vincristine-induced peripheral neuropathy in pediatric oncology patients. Cancers. https:\/\/doi.org\/10.3390\/cancers14143510","journal-title":"Cancers"},{"key":"3418_CR103","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1182\/blood-2019-126532","volume":"134","author":"ME Van De Velde","year":"2019","unstructured":"Van De Velde ME, Kaspers GJL, Abbink F, van den Heuvel-Eibrink MM, van den Bos C, van der Sluis IM, Segers H, Willems L, Van Der Werff J, Chantrain C et al (2019) Vincristine-induced peripheral neuropathy in pediatric oncology patients receiving vincristine through push injections or one-hour infusions: results of a randomized clinical trial. Blood 134:1350\u20131350. https:\/\/doi.org\/10.1182\/blood-2019-126532","journal-title":"Blood"},{"key":"3418_CR104","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2022.03.002","volume-title":"Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs","author":"RWF van Leeuwen","year":"2022","unstructured":"van Leeuwen RWF, le Comte M, Reyners AKL, van den Tweel A, van Vlijmen B, Kwee W, Wensveen B, Steeghs N, Visser O, van Gelder T et al (2022) Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs. A practical and universal tool for management, Semin Oncol. https:\/\/doi.org\/10.1053\/j.seminoncol.2022.03.002"},{"key":"3418_CR105","doi-asserted-by":"publisher","first-page":"9659","DOI":"10.1038\/s41598-020-66815-y","volume":"10","author":"P Verma","year":"2020","unstructured":"Verma P, Devaraj J, Skiles JL, Sajdyk T, Ho RH, Hutchinson R, Wells E, Li L, Renbarger J, Cooper B et al (2020) A Metabolomics Approach for Early Prediction of Vincristine-Induced Peripheral Neuropathy. Sci Rep 10:9659. https:\/\/doi.org\/10.1038\/s41598-020-66815-y","journal-title":"Sci Rep"},{"key":"3418_CR106","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1053\/cp.1999.v66.103403001","volume":"66","author":"K Villikka","year":"1999","unstructured":"Villikka K, Kivist\u00f6 KT, M\u00e4enp\u00e4\u00e4 H, Joensuu H, Neuvonen PJ (1999) Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 66:589\u2013593. https:\/\/doi.org\/10.1053\/cp.1999.v66.103403001","journal-title":"Clin Pharmacol Ther"},{"key":"3418_CR107","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/s0022-3476(81)80785-8","volume":"98","author":"WG Woods","year":"1981","unstructured":"Woods WG, O\u2019Leary M, Nesbit ME (1981) Life-threatening neuropathy and hepatotoxicity in infants during induction therapy for acute lymphoblastic leukemia. J Pediatr 98:642\u2013645. https:\/\/doi.org\/10.1016\/s0022-3476(81)80785-8","journal-title":"J Pediatr"},{"key":"3418_CR108","doi-asserted-by":"publisher","unstructured":"Wright, G.E.B., Amstutz, U., Drogemoller, B.I., Shih, J., Rassekh, S.R., Hayden, M.R., Carleton, B.C., Ross, C.J.D., and Canadian Pharmacogenomics Network for Drug Safety, C. (2019). Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes. Clin Pharmacol Ther 105, 402-410. http:\/\/dx.doi.org\/https:\/\/doi.org\/10.1002\/cpt.1179","DOI":"10.1002\/cpt.1179"},{"key":"3418_CR109","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/aps.2012.44","volume":"33","author":"Z Yan","year":"2012","unstructured":"Yan Z, Zhu ZL, Qian ZZ, Hu G, Wang HQ, Liu WH, Cheng G (2012) Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors. Acta Pharmacol Sin 33:852\u2013858. https:\/\/doi.org\/10.1038\/aps.2012.44","journal-title":"Acta Pharmacol Sin"},{"key":"3418_CR110","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.chroma.2012.12.026","volume":"1275","author":"F Yang","year":"2013","unstructured":"Yang F, Wang H, Liu M, Hu P, Jiang J (2013) Determination of free and total vincristine in human plasma after intravenous administration of vincristine sulfate liposome injection using ultra-high performance liquid chromatography tandem mass spectrometry. J Chromatogr A 1275:61\u201369. https:\/\/doi.org\/10.1016\/j.chroma.2012.12.026","journal-title":"J Chromatogr A"},{"key":"3418_CR111","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3389\/fphar.2018.00991","volume":"9","author":"F Yang","year":"2018","unstructured":"Yang F, Jiang M, Lu M, Hu P, Wang H, Jiang J (2018) Pharmacokinetic behavior of vincristine and safety following intravenous administration of vincristine sulfate liposome injection in chinese patients with malignant lymphoma. Front Pharmacol 9:991. https:\/\/doi.org\/10.3389\/fphar.2018.00991","journal-title":"Front Pharmacol"},{"key":"3418_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.771487","volume":"12","author":"QY Yang","year":"2021","unstructured":"Yang QY, Hu YH, Guo HL, Xia Y, Zhang Y, Fang WR, Li YM, Xu J, Chen F, Wang YR et al (2021) Vincristine-induced peripheral neuropathy in childhood acute lymphoblastic leukemia: genetic variation as a potential risk factor. Front Pharmacol 12:771487. https:\/\/doi.org\/10.3389\/fphar.2021.771487","journal-title":"Front Pharmacol"},{"key":"3418_CR113","doi-asserted-by":"publisher","unstructured":"Yang L, Yu L, Chen X, Hu Y, Wang B (2015) Clinical analysis of adverse drug reactions between vincristine and triazoles in children with acute lymphoblastic Leukemia. Med Sci Monit 21:1656\u20131661. https:\/\/doi.org\/10.12659\/MSM.893142","DOI":"10.12659\/MSM.893142"},{"key":"3418_CR114","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.clinthera.2008.08.011","volume":"30","author":"KY Yap","year":"2008","unstructured":"Yap KY, Chui WK, Chan A (2008) Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther 30:1385\u20131407. https:\/\/doi.org\/10.1016\/j.clinthera.2008.08.011","journal-title":"Clin Ther"},{"key":"3418_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijporl.2019.04.001","volume":"123","author":"H Zavala","year":"2019","unstructured":"Zavala H, Roby BB, Day A, Bostrom B, Sidman J, Chinnadurai S (2019) Vincristine-induced vocal cord paresis and paralysis in children. Int J Pediatr Otorhinolaryngol 123:1\u20134. https:\/\/doi.org\/10.1016\/j.ijporl.2019.04.001","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"3418_CR116","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/bf03190222","volume":"15","author":"XJ Zhou","year":"1990","unstructured":"Zhou XJ, Martin M, Placidi M, Cano JP, Rahmani R (1990) In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine. Eur J Drug Metab Pharmacokinet 15:323\u2013332. https:\/\/doi.org\/10.1007\/bf03190222","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"3418_CR117","doi-asserted-by":"publisher","unstructured":"Zhou, X.J., and Rahmani, R. (1992). Preclinical and clinical pharmacology of vinca alkaloids. Drugs 44 Suppl 4, 1\u201316; discussion 66\u201319. https:\/\/doi.org\/10.2165\/00003495-199200444-00002","DOI":"10.2165\/00003495-199200444-00002"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-022-03418-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-022-03418-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-022-03418-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T15:09:50Z","timestamp":1674227390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-022-03418-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":117,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["3418"],"URL":"https:\/\/doi.org\/10.1007\/s00204-022-03418-8","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]},"assertion":[{"value":"8 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}